• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The LRC-CPPT 1: Cholestyramine and coronary heart disease [Classics Series]

byShaidah Deghan, MSc. MDandAndrew Cheung, MD MBA
November 7, 2016
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In the 1970s, observational data suggested a direct link between serum cholesterol levels and the risk of coronary heart disease (CHD).

2. This trial was one of the first large, randomized studies to demonstrate that reducing lipid levels with cholestyramine could significantly lower death from CHD and nonfatal myocardial infarction, when compared to placebo.

Original Date of Publication: January 1984

Study Rundown: CHD remains a significant cause of death and disability around the world. In the 1970s, some observational data showed a direct relationship between serum lipid levels, particularly low-density lipoprotein cholesterol (LDL-C), and risk of CHD. It was suspected that LDL-C was heavily involved in the pathophysiology of atherosclerosis and thereby responsible for CHD. It was also understood at the time that serum lipid levels could be altered by changing diet and taking medications, though a causal relationship between cholesterol levels and CHD had yet been firmly established.

The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) was a large randomized trial started in the mid-1970s to address this relationship. Patients were largely high-school educated white men with elevated cholesterol levels. They were randomized to treatment with either cholestyramine or placebo, in addition to cholesterol-lowering diet and nutritional counseling. Treatment with cholestyramine led to significantly larger reductions in total cholesterol and LDL-C levels when compared to placebo therapy. Patients taking cholestryamine also experienced significantly lower rates of death from CHD and nonfatal myocardial infarction. Despite the study’s homogeneous population and limited generalizability, this was one of the first large-scale randomized trials to demonstrate a consistent reduction in CHD after lipid lowering therapy.

Click to read the study in JAMA

In-Depth [randomized double-blind controlled study]: This double-blind, placebo-controlled, randomized trial was conducted at 12 sites in the United States. Men between 35 and 59 years of age, with a plasma cholesterol level ≥6.9 mmol/L (265 mg/dL) and LDL-C level ≥4.9 mmol/L (190 mg/dL) were recruited for the study. Exclusion criteria included triglyceride levels averaging >3.387 mmol/L (300 mg/dL), type III hyperlipopriteinemia, clinical manifestations of CHD (myocardial infarction, angina pectoris, ECG abnormalities, heart failure), diabetes mellitus, hypothyroidism, nephrotic syndrome, obesity, and hypertension. A total of 3806 participants were randomized to treatment with either cholestyramine 24 g daily or an equivalent amount of placebo and followed for an average of 7.4 years. All patients were offered a cholesterol-lowering diet along with nutritional counseling. The primary endpoint was a composite of death from CHD and nonfatal myocardial infarction. Other endpoints were all-cause mortality, atherothrombotic brain infarction, and arterial peripheral vascular disease.

RELATED REPORTS

Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

Diabetes, stroke, and coronary heart disease associated with increased mortality among Black adults: Jackson Heart Study

Compared to placebo, treatment with cholestyramine significantly reduced total cholesterol (8.5%, p < 0.001) and LDL-C (12.6%, p < 0.001). At 7 years, the primary endpoint occurred significantly less frequently in the cholestyramine group as compared with the placebo group (8.1% vs. 9.8%; risk reduction 19%, 90%CI 3 to 32%, p < 0.05). There were significantly fewer CHD deaths (1.6% vs. 2.0%; risk reduction 24%) and nonfatal myocardial infarctions (6.8% vs. 8.3%; risk reduction 19%) in patients taking cholestyramine. There were no significant differences between the two groups in the incidence of brain infarction or peripheral vascular disease, and no difference in all-cause mortality. Gastrointestinal side effects were common during the trial. In the first year, the rate of such side effects were significantly higher in the cholestyramine group (68% vs. 43%). These rates were quite similar by year 7 (29% vs. 26%).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: cholesterolcoronary heart diseaselrc-cpptlrc-cppt 1
Previous Post

Psychotropic medications reduce further violent crimes in released prisoners

Next Post

Flavored e-cigarette use associated with higher smoking risks in youth

RelatedReports

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease

February 6, 2023
Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]
Cardiology

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

November 22, 2022
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Diabetes, stroke, and coronary heart disease associated with increased mortality among Black adults: Jackson Heart Study

October 29, 2022
Gender conformity influences use of laxatives and muscle-building products
Cardiology

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

September 20, 2022
Next Post

Flavored e-cigarette use associated with higher smoking risks in youth

Unmet healthcare need in adolescence linked to poor adult outcomes

Therapy advancements not correlated with improved health status for adult survivors of childhood cancer

Decreased prevalence of HPV among vaccinated young females

State legislation linked to increase in HPV vaccination in teenage girls

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options